Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Osteoporosis in 2011

Osteoporosis therapy—dawn of the post-bisphosphonate era

Nature Reviews Endocrinology volume 8, pages 76–78 (2012)Cite this article

Subjects

Over the past decade, investigators have actively searched for safer therapeutic approaches to replace or complement the use of bisphosphonates and/or parathyroid hormone, exploring both antiresorptive and osteoanabolic pathways. Besides marked progress in basic research, the year 2011 has seen several compounds for the treatment of osteoporosis enter or progress within clinical trials.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cosman, F. et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis. J. Bone Miner. Res. 26, 503–511 (2011).

    Article  CAS  PubMed  Google Scholar 

  2. Balemans, W. et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Gen. 10, 537–543 (2001).

    Article  CAS  PubMed  Google Scholar 

  3. Balemans, W. et al. Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39, 91–97 (2002).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Padhi, D. et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26, 19–26 (2011).

    Article  CAS  PubMed  Google Scholar 

  5. Eastell, R. et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J. Bone Miner. Res. 26, 530–537 (2011).

    Article  CAS  PubMed  Google Scholar 

  6. Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756–765 (2009).

    Article  CAS  PubMed  Google Scholar 

  7. Boonen, S. et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J. Clin. Endocrinol. Metab. 96, 1727–1736 (2011).

    Article  CAS  PubMed  Google Scholar 

  8. Bone, H. G. et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96, 972–980 (2011).

    Article  CAS  PubMed  Google Scholar 

  9. Eisman, J. A. et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J. Bone Miner. Res. 26, 242–251 (2011).

    Article  CAS  PubMed  Google Scholar 

  10. Eastell, R. et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. J. Bone Miner. Res. 26, 1303–1312 (2011).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Endocrine Unit, 188 Longwood Avenue, Boston, 02115, MA, USA

    Roland Baron

Authors
  1. Roland Baron
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares associations with the following companies: Amgen (consultant), Arcarios (consultant), Bone Therapeutics (consultant), Merck (consultant; grant/research support), Novartis (consultant), Roche (consultant).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baron, R. Osteoporosis therapy—dawn of the post-bisphosphonate era. Nat Rev Endocrinol 8, 76–78 (2012). https://doi.org/10.1038/nrendo.2011.207

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2011.207

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing